Mustang Bio

Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment

placeNew York City, New York, United States calendar_todayFounded 2015 groups80 employees language mustangbio.com

Registered entities

Innovation

4 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 69 times.

YearFilings
20191
20201
20213
20223
20232

Social engagement

Social engagement: 9.4K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

4 investors on record.

Investor typeCountShare
Private equity125%
Bank & private debt125%
Other / undisclosed250%
Coming soon